Evotec SE (NASDAQ: EVO)
$4.4700
+0.2000 ( +3.00% ) 50.2K
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Market Data
Open
$4.4700
Previous close
$4.2700
Volume
50.2K
Market cap
$1.54B
Day range
$4.3100 - $4.4600
52 week range
$2.8500 - $10.0870
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Form 6-K | 8 | Nov 29, 2024 |
6-k | Form 6-K | 2 | Nov 22, 2024 |
6-k | Form 6-K | 2 | Nov 15, 2024 |
6-k | Form 6-K | 7 | Nov 06, 2024 |
6-k | Form 6-K | 33 | Aug 14, 2024 |
20-f | Annual reports | 207 | Aug 14, 2024 |
6-k | Form 6-K | 5 | Aug 06, 2024 |
6-k | Form 6-K | 4 | Jun 10, 2024 |
6-k | Form 6-K | 4 | May 22, 2024 |
nt | Quarterly Reports | 1 | Apr 30, 2024 |